Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Klein, C. A. Articles by Goulmy, E. Search for Related Content PubMed PubMed Citation Articles by Klein, C. A. Articles by Goulmy, E. Social Bookmarking                      What's this?

¹ Department of Immunology, Klinikum Innenstadt, Ludwig-Maximilians University, 80336 Munich, Germany
² Chirurgische Klinik, Klinikum Innenstadt, Ludwig-Maximilians University, 80336 Munich, Germany
³ Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, Netherlands

Address correspondence to Els Goulmy, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Phone: 31-71-526-1966; Fax: 31-71-521-6751; E-mail: E.A.J.M.Goulmy{at}lumc.nl

Allogeneic stem cell transplantation (SCT) can induce curative graft-versus-tumor reactions in patients with hematological malignancies and solid tumors. The graft-versus-tumor reaction after human histocompatibility leukocyte antigen (HLA)-identical SCT is mediated by alloimmune donor T cells specific for polymorphic minor histocompatibility antigens (mHags). Among these, the mHag HA-1 was found to be restricted to the hematopoietic system. Here, we report on the HA-1 ribonucleic acid expression by microdissected carcinoma tissues and by single disseminated tumor cells isolated from patients with various epithelial tumors. The HA-1 peptide is molecularly defined, as it forms an immunogenic peptide ligand with HLA-A2 on the cell membrane of carcinoma cell lines. HA-1–specific cytotoxic T cells lyse epithelial tumor cell lines in vitro, whereas normal epithelial cells are not recognized. Thus, HA-1–specific immunotherapy combined with HLA-identical allogeneic SCT may now be feasible for patients with HA-1⁺ carcinomas.

Key Words: stem cell transplantation • graft-versus-tumor • carcinomas • cytotoxic T cells • minimal residual disease

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kawase, T., Akatsuka, Y., Torikai, H., Morishima, S., Oka, A., Tsujimura, A., Miyazaki, M., Tsujimura, K., Miyamura, K., Ogawa, S., Inoko, H., Morishima, Y., Kodera, Y., Kuzushima, K., Takahashi, T. (2007). Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 110: 1055-1063 [Abstract] [Full Text]  
• Hartmann, C. H., Klein, C. A. (2006). Gene expression profiling of single cells on large-scale oligonucleotide arrays. Nucleic Acids Res 34: e143-e143 [Abstract] [Full Text]  
• Rice, J., Dunn, S., Piper, K., Buchan, S. L., Moss, P. A., Stevenson, F. K. (2006). DNA Fusion Vaccines Induce Epitope-Specific Cytotoxic CD8+ T Cells against Human Leukemia-Associated Minor Histocompatibility Antigens.. Cancer Res. 66: 5436-5442 [Abstract] [Full Text]  
• Carnevale-Schianca, F., Cignetti, A., Capaldi, A., Vitaggio, K., Vallario, A., Ricchiardi, A., Sperti, E., Ferraris, R., Gatti, M., Grignani, G., Rota-Scalabrini, D., Geuna, M., Fizzotti, M., Sangiolo, D., Sottile, A., De Rosa, G., Bucci, A. R., Lambertenghi-Deliliers, G., Benedetti, E., Nash, R., Aglietta, M. (2006). Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 107: 3795-3803 [Abstract] [Full Text]  
• Mommaas, B., Stegehuis-Kamp, J. A., van Halteren, A. G., Kester, M., Enczmann, J., Wernet, P., Kogler, G., Mutis, T., Brand, A., Goulmy, E. (2005). Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood 105: 1823-1827 [Abstract] [Full Text]  
• Tykodi, S. S., Warren, E. H., Thompson, J. A., Riddell, S. R., Childs, R. W., Otterud, B. E., Leppert, M. F., Storb, R., Sandmaier, B. M. (2004). Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens. Clin. Cancer Res. 10: 7799-7811 [Abstract] [Full Text]  
• Akatsuka, Y., Nishida, T., Kondo, E., Miyazaki, M., Taji, H., Iida, H., Tsujimura, K., Yazaki, M., Naoe, T., Morishima, Y., Kodera, Y., Kuzushima, K., Takahashi, T. (2003). Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens. J. Exp. Med. 197: 1489-1500 [Abstract] [Full Text]  
• Barrett, A. J., Rezvani, K., Solomon, S., Dickinson, A. M., Wang, X. N., Stark, G., Cullup, H., Jarvis, M., Middleton, P. G., Chao, N. (2003). New Developments in Allotransplant Immunology. ASH Education Book 2003: 350-371 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS